乳腺浸润性导管癌组织中Mfn2的表达变化及临床意义

Expression changes of Mfn2 in infiltrating ductal carcinoma of breast and the clinical significance

目的观察乳腺浸润性导管癌组织中线粒体融合蛋白2(Mfn2)的表达变化,并探讨其临床意义。方法采用免疫组化法检测116例份乳腺浸润性导管癌组织(观察组)、10例份正常乳腺导管上皮组织(对照组)Mfn2,分析Mfn2表达与乳腺浸润性导管癌临床病理参数的相关性。结果观察组及对照组Mfn2阳性率分别为44.82%(52/116)、90.00%(9/10),两组比较,P<0.05。Mfn2表达与乳腺浸润性导管癌淋巴结转移、组织学分级、TNM分期、雌激素受体、孕激素受体、人表皮生长因子受体-2有关(P均<0.05)。结论乳腺浸润性导管癌组织中Mfn2的表达降低,其可能在乳腺浸润性导管癌的发生、发展过程中起作用。

Objective To observe the expression changes of mitofusin 2( Mfn2) in infiltrating ductal carcinoma of breast and to investigate its clinical significance. Methods The immunohistochemical SP method was used to assess the expression of Mfn2 in 116 cases of infiltrating ductal carcinoma of breast( observation group) and 10 cases of normal breast ductal epithelial tissues( control group). The relationships between Mfn2 expression and the clinicopathological parameters of breast infiltrating ductal carcinoma patients were analyzed. Results The positive expression rates of Mfn2 in the observation and control groups were 44. 82%( 52 /116) and 90. 00%( 9 /10),respectively( all P < 0. 05). The Mfn2 expression was related with lymph node metastasis,histological grade,TNM staging,estrogen receptor,progesterone receptor and epidermal growth factor receptor-2 of breast infiltrating ductal carcinoma( all P < 0. 05). Conclusion The Mfn2 expression is decreased in the breast infiltrating ductal carcinoma tissues,which may play an important role in the occurrence and development of infiltrating ductal carcinoma of breast